Windlas Biotech, Mateon Therapeutics partner to launch combined lung therapy and AI telemedicine solution

Windlas Biotech, an Indian pharma contract drug development and manufacturing organisation, has entered into a partnership with Mateon Therapeutics, a US-based oncology company focusing on TGF-β inhibitors as therapies against cancers and infectious diseases, to launch an integrated solution for respiratory wellness in India.

In a statement, the company informed, “The product, PulmoHeal is a broad-spectrum, lung therapy food supplement that is supported by a multi-centre rigorous clinical study and integrated with its own telemedicine AI-based platform to offer continuous 360^O care for patients in India. Developed from extract of the indigenous plant Artemisia, the active component of PulmoHeal, Artemisinin, has been known to exhibit multiple pharmacological activity against inflammation, viral infections, and lung repair. PulmoHeal can be taken periodically by those affected by respiratory viral infection, asthma, hay fever, or smokers and even those living in smog infested cities to improve their lung health and breathing functions.”

The company also informed that the combined drug + AI telemedicine solution consists of three components:

1) The drug PulmoHeal, clinically shown to be effective against respiratory problems

2) An AI lung health assessment tool called ArtiHealth

3) A post-marketing survey (PMS) platform to crowd-source user experience for new indications

Hitesh Windlass, MD, Windlas Biotech, commented, “PulmoHeal is a unique combination of cutting-edge manufacturing, clinical drug development, and artificial intelligence (AI), which harnesses the power of traditional and modern science. The ARTIHealth model can be replicated for a range of therapies including monitoring Covid-19 infection. Our work with Mateon on PulmoHeal has been accepted by leading peer-reviewed journals in modern medicine and we shall continue to build on our momentum in bringing 360^o solution to all facets of healthcare.”

Saran Saund, CBO, Mateon, commented, “To date, SOC for mild and moderate COVID patients is primarily limited to self-quarantine due to a significant strain of medical resources, without any drug therapy. Such patients can benefit from PulmoHeal. We are optimistic that our solution will be beneficial even beyond current pandemic by empowering the patients and reducing burden on health care providers”.

Dr Vuong Trieu, CEO and Chairman of Mateon said, “We are pleased to be able to leverage on the deep tradition of Indian medicine and advance artificial intelligence and supercomputing technologies under one umbrella to create this innovative solution to healthcare, one which we hope to replicate throughout the world across multiple indications. Through our post-marketing survey platform, we hope to democratise drug development through patient-driven research.”